NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • #TrumpTrade
  • 24-HOUR Pass →
  • Invest ↗
Sign in Subscribe

Riding the New Nuclear Wave: Canaccord Slaps Buy Rating and $10 PT on Terra Innovatum

Canaccord Genuity starts coverage on Terra Innovatum with a Buy rating and $10 price target, highlighting big potential in micro-modular nuclear reactors amid rising demand for clean, reliable energy.

Riding the New Nuclear Wave: Canaccord Slaps Buy Rating and $10 PT on Terra Innovatum
Credit: Vanja Savic
Already have an account? Sign in.
02/20/2026 · 6:48 AM
NKLR
/ Read more

Feed↓

Corcept Director Drops $3.35 Million on 100,000 Shares – Strong Insider Buy Signal
03/19/2026 · 5:44 PM

Corcept Director Drops $3.35 Million on 100,000 Shares – Strong Insider Buy Signal

Corcept Therapeutics director Leonard Baker Jr. purchased 100,000 common shares at ~$33 each in open-market buys.

/ Subscriber only
FedEx Raises Full-Year Profit Outlook After Strong Q3 Results, Freight Spin-Off On Track
Featured/ 03/19/2026 · 4:37 PM

FedEx Raises Full-Year Profit Outlook After Strong Q3 Results, Freight Spin-Off On Track

FedEx (FDX) raised its full-year fiscal 2026 adjusted EPS guidance to $19.30–$20.10 and revenue growth forecast to 6.0%-6.5% after strong Q3 results. Adjusted earnings hit $5.25 per share, beating estimates.

/ Subscriber only
Roche Abandons Emugrobart – Clears Path for Scholar Rock’s Apitegromab to Dominate SMA
Featured/ 03/19/2026 · 3:28 PM

Roche Abandons Emugrobart – Clears Path for Scholar Rock’s Apitegromab to Dominate SMA

Roche halts emugrobart development, clearing path for Scholar Rock's apitegromab to dominate SMA muscle therapy market. Cantor sees multi-billion potential.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe